Jeffery A Dusek1,2, Rachael L Rivard1,3, Kristen H Griffin4, Michael D Finch4. 1. UH Connor Integrative Health Network, University Hospitals, Cleveland, OH, USA. 2. Department of Family Medicine and Community Health, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 3. Center for Evaluation and Survey Research, HealthPartners Institute, Minneapolis, MN, USA. 4. Children's Minnesota Research Institute, Children's Minnesota, Minneapolis, MN, USA.
Abstract
Background: Prior research has reported that integrative medicine (IM) therapies reduce pain in inpatients, but without controlling for important variables. Here, the authors extend prior research by assessing pain reduction while accounting for each patient's pain medication status and clinical population. Methods: The initial data set consisted of 7,106 inpatient admissions, aged ≥18 years, between July 16, 2012, and December 15, 2014. Patients' electronic health records were used to obtain data on demographic, clinical measures, and pain medication status during IM. Results: The final data set included first IM therapies delivered during 3,635 admissions. Unadjusted average pre-IM pain was 5.33 (95% confidence interval [CI]: 5.26 to 5.41) and post-IM pain was 3.31 (95% CI: 3.23 to 3.40) on a 0-10 scale. Pain change adjusted for severity of illness, clinical population, sex, treatment, and pain medication status during IM was significant and clinically meaningful with an average reduction of -1.97 points (95% CI: -2.06 to -1.86) following IM. Adjusted average pain was reduced in all clinical populations, with largest and smallest pain reductions in maternity care (-2.34 points [95% CI: -2.56 to -2.14]) and orthopedic (-1.71 points [95% CI: -1.98 to -1.44]) populations. Pain medication status did not have a statistically significant association on pain change. Decreases were observed regardless of whether patients were taking narcotic medications and/or nonsteroidal anti-inflammatory drugs versus no pain medications. Conclusions: For the first time, inpatients receiving IM reported significant and clinically meaningful pain reductions during a first IM session while accounting for pain medications and across clinical populations. Future implementation research should be conducted to optimize identification/referral/delivery of IM therapies within hospitals. Clinical Trials.gov #NCT02190240.
Background: Prior research has reported that integrative medicine (IM) therapies reduce pain in inpatients, but without controlling for important variables. Here, the authors extend prior research by assessing pain reduction while accounting for each patient's pain medication status and clinical population. Methods: The initial data set consisted of 7,106 inpatient admissions, aged ≥18 years, between July 16, 2012, and December 15, 2014. Patients' electronic health records were used to obtain data on demographic, clinical measures, and pain medication status during IM. Results: The final data set included first IM therapies delivered during 3,635 admissions. Unadjusted average pre-IM pain was 5.33 (95% confidence interval [CI]: 5.26 to 5.41) and post-IM pain was 3.31 (95% CI: 3.23 to 3.40) on a 0-10 scale. Pain change adjusted for severity of illness, clinical population, sex, treatment, and pain medication status during IM was significant and clinically meaningful with an average reduction of -1.97 points (95% CI: -2.06 to -1.86) following IM. Adjusted average pain was reduced in all clinical populations, with largest and smallest pain reductions in maternity care (-2.34 points [95% CI: -2.56 to -2.14]) and orthopedic (-1.71 points [95% CI: -1.98 to -1.44]) populations. Pain medication status did not have a statistically significant association on pain change. Decreases were observed regardless of whether patients were taking narcotic medications and/or nonsteroidal anti-inflammatory drugs versus no pain medications. Conclusions: For the first time, inpatients receiving IM reported significant and clinically meaningful pain reductions during a first IM session while accounting for pain medications and across clinical populations. Future implementation research should be conducted to optimize identification/referral/delivery of IM therapies within hospitals. Clinical Trials.gov #NCT02190240.
Authors: Brent A Bauer; Susanne M Cutshall; Laura J Wentworth; Deborah Engen; Penny K Messner; Christina M Wood; Karen M Brekke; Ryan F Kelly; Thoralf M Sundt Journal: Complement Ther Clin Pract Date: 2009-07-14 Impact factor: 2.446
Authors: Lori P Montross-Thomas; Emily A Meier; Kimberly Reynolds-Norolahi; Erin E Raskin; Daniel Slater; Paul J Mills; Lauray MacElhern; Gene Kallenberg Journal: J Altern Complement Med Date: 2017-01-23 Impact factor: 2.579
Authors: Allison R Mitchinson; Hyungjin Myra Kim; Jack M Rosenberg; Michael Geisser; Marvin Kirsh; Dolores Cikrit; Daniel B Hinshaw Journal: Arch Surg Date: 2007-12
Authors: Jeffery A Dusek; Kristen H Griffin; Michael D Finch; Rachael L Rivard; David Watson Journal: J Altern Complement Med Date: 2018-02-23 Impact factor: 2.579
Authors: Kent C Nate; Kristen H Griffin; Jon B Christianson; Jeffery A Dusek Journal: Evid Based Complement Alternat Med Date: 2015-11-26 Impact factor: 2.629